netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Topotecan found 12 matches


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA183: Cervical cancer (recurrent) - topotecan  (08.01.05)
link in drug section NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (08.01.05)
link in drug section NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (08.01.05)
link in drug section NICE TA184: Lung cancer (small-cell) - topotecan (08.01.05)
link in drug section NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (08.01.05)
link in drug section NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.02)
link in drug section NICE TA389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (08.01.02)
link in drug section NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer: (08.01.05)


 
netFormulary